Renal Cell Carcinoma

RENAL CELL CARCINOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

First-Ever Prospective Trial in Pediatric RCC Reports Results

The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%.
Reliability of Laboratory-Developed Tests Called Into Question

A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials

Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
Metastatic Renal Cell Carcinoma: Metastasectomy Improves Outcomes

There is evidence to support the role of metastasectomy in providing patients with mRCC an improvement in certain clinical outcomes.
Renal Cell Carcinoma Outcomes: Does Hemodialysis Make a Difference?

Hemodialysis was found to be a poor prognostic factor for patients with RCC.

VIDEO SERIES

Tivozanib for RCC

Genitourinary Oncology: A Peek Over the Horizon

Immunotherapy of Renal Cell Carcinoma

Targeted Therapies for Renal Cell Carcinoma

Genetics and Heterogeneity

Genetic Predisposition to Kidney Cancers

Personalized Medicines for Kidney Cancers

Drugs in the Pipeline

Resistance to Therapy Among Kidney Cancers

Targeted Therapy

The Role of Neoadjuvant Tx

Sx Options – Ablative Techniques

Sx Options – Lymph Node

Sx Options – Cytoreductive Nephrectomy

TKIs – First-Line Therapy

TKIs – Second-Line Therapy

Biomarkers in RCC

The MET Pathway

Checkpoint Inhibitors

RENAL CELL CARCINOMA NEWS

A TURBT allows examination beyond the bladder.

Laparoscopic Partial Nephrectomy and Percutaneous Cryoablation Offer Similar Oncologic Outcomes

October 9, 2020

surgery-team

Metastasectomy Survival Benefit in mRCC Cases Confirmed

October 6, 2020

Gene Signatures are Potential Biomarkers for ccRCC

October 5, 2020

The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.

Gene Expression Signatures May be Predictive for Nivolumab in ccRCC

October 5, 2020

ctDNA Concordant with Tissue Genomic Analysis in RCC

October 5, 2020

Next post in Renal Cell Carcinoma

A TURBT allows examination beyond the bladder.

Laparoscopic Partial Nephrectomy and Percutaneous Cryoablation Offer Similar Oncologic Outcomes